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acting as gene regulators by repressing translation or by
inducing degradation of the target RNA transcripts. Altered
expression of miRNAs may be involved in the pathogenesis
of many severe human diseases, opening new avenues in the
field of therapeutic strategies, i.e., miRNA targeting or miRNA
mimicking. In this context, the efficient and non-toxic delivery
of premiRNA and antimiRNA molecules might be of great in-
terest. The aim of the present paper is to determine whether an
argininocalix[4]arene is able to efficiently deliver miRNA, pre-
miRNA, and antimiRNA molecules to target cells, preserving
their biological activity. This study points out that (1) the
toxicity of argininocalix[4]arene 1 is low, and it can be pro-
posed for long-term treatment of target cells, being that this
feature is a pre-requisite for the development of therapeutic
protocols; (2) the delivery of premiRNA and antimiRNA mol-
ecules is efficient, being higher when compared with reference
gold standards available; and (3) the biological activity of the
premiRNAs and antimiRNAs is maintained. This was demon-
strated using the argininocalix[4]arene 1 in miRNA therapeu-
tic approaches performed on three well-described experimental
model systems: (1) the induction of apoptosis by antimiR-221
in glioma U251 cells; (2) the induction of apoptosis by pre-
miR-124 in U251 cells; and (3) the inhibition of pro-inflamma-
tory IL-8 and IL-6 genes in cystic fibrosis IB3-1 cells. Our re-
sults demonstrate that the argininocalix[4]arene 1 should be
considered a very useful delivery system for efficient transfer
to target cells of both premiRNA and antimiRNA molecules,
preserving their biological activity.Received 22 January 2019; accepted 17 September 2019;
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MicroRNAs (miRNAs, miRs) are short non-coding RNA molecules
that act as gene regulators by repressing translation or by inducing
degradation of the target RNA transcripts.1–4 Emerging evidence sug-
gests that the altered expression of miRNAs may be involved in the
pathogenesis of several human diseases, such as Alzheimer’s disease,
type 1 diabetes, cancer, cardiovascular, inflammatory, and genetic dis-
eases.5–11 The involvement of miRNAs in human pathologies is docu-748 Molecular Therapy: Nucleic Acids Vol. 18 December 2019 ª 2019
This is an open access article under the CC BY-NC-ND license (httpmented by an increasing nomenclature describing miRNA classes
such as oximiRNAs (i.e., miRNAs involved in the oxidative stress),12
apoptomiRNAs (i.e., miRNAs involved in apoptosis),13 oncomiR-
NAs, and metastamiRNAs (i.e., miRNA associated with tumor pro-
gression and metastasis, respectively).14,15 This field of biological
investigation is important not only for basic research, but also in
applied biomedicine. In fact, approaches based on miRNAs targeting
(miRNA therapeutics)16–25 can be designed to inhibit tumor cell
growth and metastasis and to counteract the resistance of tumor cells
to anti-cancer drugs.15,17
In the case of miRNAs directly or indirectly causing pathologies (such
as oncomiRNAs and metastamiRNAs in cancer), their functions can
be inhibited or fully suppressed with antagomiR molecules,17,21,26
while in the case of miRNAs downregulated in diseases and, for
this reason, contributing to clinical complications caused by their dys-
regulated expression, their biological activity can be rescued with the
use of miRNA mimics (for instance, transfection with premiRNA
molecules).17,22,23,27 For instance, Chan et al.28 demonstrated that
sequence-specific functional inhibition of oncomiR-138 in malignant
gliomas prevents tumor sphere formation in vitro and impedes
tumorigenesis in vivo. In addition, Wagenaar et al.29 were able to
deregulate the transcriptional network in hepatocellular carcinomas
by targeting miR-21 with sequence-specific antagomiR, thus inducing
a significant de-repression of direct targets of miR-21, which led to
loss of viability in the majority of hepatocarcinoma cell lines tested.
In another example, Ma et al.30 reported that therapeutic silencing
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Figure 1. Effects of Argininocalix[4]arene 1 on Cell Morphology and Cell Growth
(A) Molecular structure of argininocalix[4]arene 1. (B–E) Effects of argininocalix[4]arene 1 onmorphology (B and D) and cell proliferation (C and E) of U251 glioma (B andC) and
leukemic K562 (D and E) cells, analyzed after 48 (B and D) and 72 (C and E) h of cell culture in the presence of the indicated concentration of argininocalix[4]arene 1. The
average ± SD of three indipendent experiments are shown in panels C and E.
www.moleculartherapy.orgAs far as miRNA targeting is concerned, the vehiculation of miRNAs
and antagomiRNAs to target cells is a key issue.25,31–34 In fact,
miRNA vehicles not only are essential to transfer miRNA-based mol-
ecules into target cells, but also have a key role in avoiding their degra-
dation. A large number of vehicles were tested both in vitro and
in vivo, but most of them present several issues, such as inappropriate
biodistribution, disruption, and saturation of endogenous RNA ma-
chinery and high toxicity.31
Concerning the delivery of nucleic acids, we reported35–38 on the use
of macrocyclic vectors based on calix[4]arene amphiphiles for the
transport of plasmid DNA into cells. In particular, the arrangement
of only four units of a basic amino acid,37 such as arginine and lysine,
linked at the aromatic para position of the calixarene scaffold, gave
rise to new, potent, non-viral delivery systems. The parallel spatial or-
ganization of the amino acid units characterizing these derivatives
was particularly effective on the transfection process, perhaps for
the significant presence of available primary a-amino groups with
respect to the usual oligoarginine and oligolysine peptides used for
these purposes where these groups are involved in amide bonds.
These featuresmake in particular argininocalix[4]arene 1 (Figure 1A),
the progenitor of a new class of efficient synthetic cationic surfactants,
which could constitute a valuable alternative to commercially avail-
able formulations in transfection protocols.37,38The remarkable properties of the calixarene-based molecule argini-
nocalix[4]arene 1 as DNA vector seemed correlated also to the
length of the long nucleic acid filament used in that case, in partic-
ular for the condensation process,35,38 so that the possibility of the
use of argininocalix[4]arene 1 for the transfection of oligonucleo-
tides and miRNAs was not easily expected. Nevertheless, starting
from the evidence that this molecule showed an impressive ability
to vehicle DNA with respect to a larger library of calixarene-based
molecules, it was chosen to initiate the investigation of miRNA
delivery.
The U251 glioma cell line,39 the cystic fibrosis IB3-1 cell line,40 and
the chronic myelogenous leukemia K562 cell line41 were chosen as
cellular model systems. U251 and IB3-1 cell lines grow attached to
the flasks,39,40 while K562 cells grow in suspension.41 For miRNA tar-
gets, miR-221-3p was considered as a model for antimiRNA therapy,
while miR-210-3p, miR-124-3p, and miR-93-5p were considered as
model systems for miRNA replacement therapy. The effects of
miRNA targeting and/or mimicking on the proposed cellular model
systems are well known.42–48 Targeting of miR-221-3p facilitates
apoptosis of U251 glioma cells,42,43 miR-210-3p mimicking causes
inhibitory effects on the target mRNA BCL11A,44 miR-124-3p
mimicking is associated with induction of apoptosis of U251 glioma















































































Figure 2. Effects of Argininocalix[4]arene 1 on Cell Morphology and Cell Growth, Comparison with Lipofectamine RNAiMAX
(A–F) Effects of argininocalix[4]arene 1 (A, C, D, and F) and lipofectamine RNAiMAX (B, C, E, and F) on vitality (A, B, D, and E) and cell proliferation (C and F) of U251 glioma
(A–C) and leukemic K562 (D–F) cells, analyzed after 48 h of cell culture in the presence of the indicated concentration of argininocalix[4]arene 1 or Lipofectamine RNAiMAX.
The average ± SD of three indipendent experiments are shown.
Molecular Therapy: Nucleic Acidsexpression of interleukin-8 (IL-8) and interleukin-6 (IL-6) in several
cellular model systems.47,48
RESULTS
Effects of Argininocalix[4]arene 1 on Cell Morphology and Cell
Growth
One of the major issues associated with the use of commercially avail-
able vehicles for the delivery of bioactive RNA- and DNA-based
molecules is the high toxicity and anti-proliferative effects of these
compounds. Of course, in the case of any proposed protocol for
miRNA therapeutics, the possibility of performing long-term treat-
ment is required. As the paper by Bagnacani et al.37 just considered
short-term (5 h exposure) treatments, the first set of experiments
were designed to verify the possibility to perform exposure to argini-
nocalix[4]arene 1 for longer periods of time. Effects on cell
morphology and cell growth were determined at 48 and 72 h after
the transfection, testing different concentrations of calixarene-based
molecule (0.6, 1.2, 2.5, 5, and 10 mM). The argininocalix[4]arene 1
was maintained in contact with the cells at the indicated concentra-
tions for all the treatment time. As shown in Figure 1B, 48 h after
the transfection no major differences in morphology were found in
the presence of the argininocalix[4]arene 1, while only a slight alter-750 Molecular Therapy: Nucleic Acids Vol. 18 December 2019ation of cell morphology was detected when 10 mM of argininocalix
[4]arene 1 was used.
In addition, Figure 1C demonstrates that argininocalix[4]arene 1 does
not show antiproliferative effects. Lack of inhibitory effects of argini-
nocalix[4]arene 1 on morphology and cell growth were confirmed
using the K562 cell system (Figures 1D and 1E). Comparisonwith Lip-
ofectamine RNAiMAX is shown in Figure 2, which analyzes vitality
(Figures 2A, 2B, 2D, and 2E) and cell growth (Figures 2C and 2F) after
48 h inU251 andK562 cells. A slight decrease of viability was observed
for argininocalix[4]arene 1 and Lipofectamine RNAiMAX when used
at high concentrations. The decrease of the proportion of live U251
and K562 cells is not unexpected, since it is well established that
most of the transfection reagents are to some extent cytotoxic to the
cells. However, inhibition of cell growth was detected using Lipofect-
amine RNAiMAX at the optimal concentration for RNA transfection,
in agreement with other published studies49–53 (Figures 2C and 2F).
On the basis of the results shown in Figures 1 and 2, the experiments
presented in this study and related to the analysis of the biological
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Figure 3. Transfection of Mature Fluorescent miRNA
Human glioma U251 cells were cultured in absence (Ctrl) or in
the presence of the indicated concentrations (70 and 200 nM) of
fluorescein labelled mature miR-210, either free or vehiculated
with 10 mM of argininocalix[4]arene 1. Mature miRNA internali-
zation was verified using FACS analysis. (A) Representative
fluorescence plots. (B) Overlay plot.
www.moleculartherapy.orgTransfection of Mature miRNAs Using Argininocalix[4]arene 1
In order to evaluate the transfection ability of argininocalix[4]arene 1,
a synthetic mature miRNA conjugated with fluorescein was first em-Molecular Tployed, allowing verifying miRNA internalization us-
ing rapid methods, as fluorescence microscopy and
FACS (fluorescence-activated cell sorting) analysis.
As indicated in Figure 3, the adherent U251 cell line
displayed a sharp change in fluorescence intensity
when the cells were transfected with the fluorescent
mature miR-210, using argininocalix[4]arene 1 at
final concentration of 10 mM. For this preliminary
experiment, the same argininocalix[4]arene 1 con-
centration previously reported by Bagnacani and col-
leagues37 for DNA transfection was used. U251 cells
transfected with two different concentrations of
miR-210 (70 nM and 200 nM) were analyzed by
FACS (Figures 3A and 3B), and fluorescence variation
with respect to the control cells was reported. As indi-
cated in Figure 3B, when miR-210 was added with no
vehicle, no variation of fluorescence was detected,
while the transfection of miR-210 with argininocalix
[4]arene 1 lead to a shift in fluorescence proportional
to the miR-210 concentration.
The data obtained by fluorescence analysis were then
confirmed by the quantification of intracellular levels
of miRNAs after the transfection using qRT-PCR (Fig-
ures 4A–4D). Comparison with the cell line K562 was
also considered, since K562 cells are known to be very
difficult to be transfected. Moreover, an additional
mature miRNA (miR-221) was transfected to exclude
that the interaction between argininocalix[4]arene 1
and mature miRNA was limited to a specific miRNA
sequence. As reported in Figures 4A and 4C, CT (cycle
threshold) values before (white rhombuses) and after
(black squares) transfection were determined for
both miRNAs miR-210 and miR-221 and for both
U251 and K562 cell lines. In all cases, a CT decrease
was observed in the presence of vector argininocalix
[4]arene 1, indicating that the miR-221 and miR-210
content was sharply increased. Concerning the starting
levels of miR-221 and miR-210 in U251 and K562 celllines, while miR-210 seems to have similar CT values in the two cells
lines, miR-221 is more expressed in the U251 cell line with respect to
K562 cells. Moreover, miRNA accumulation in transfected cellsherapy: Nucleic Acids Vol. 18 December 2019 751
Figure 4. Transfection of Mature miRNAs and premiRNAs with Argininocalix[4]arene 1
(A–D) Mature miRNA transfection. Two different cell lines, U251 (A and B) and K562 (C and D), were employed. Cells were characterized for their starting miR-210 (white
rhombuses) and miR-221 (white squares) levels, comparing CT (cycle threshold) values. Moreover, measured CT values after transfection were reported: black rhombuses
(miR-210) and black squares (miR-221) (A and C). In (B) and (D), the fold change in transfected cells (white boxes/bars) with respect to control samples (black boxes/bars) was
(legend continued on next page)
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www.moleculartherapy.org(open bars) was compared with those found in the no-transfected sam-
ple (black bars), and the results are depicted in Figures 4B and 4D. For
both miRNAs and in both cell lines, significant (p < 0.001) increase of
miRNA levels after transfection was detected, in agreement with CT
changes.
In order to increase miRNA levels into target cells, one of the most
useful methods is to deliver synthetic premiRNA molecules into
them. As for miRNAs, cationic liposomes are exploited, interacting
with the negative charges present in the premiRNA structure and
forming a complex that is internalized by the cells. Lipofectamine
(Invitrogen) or siPORT (Ambion) are two examples of reagents
commonly used for this purpose.53 Generally, these reagents exhibit
high toxicity and a very variable transfection efficiency, dependent
on the employed cell line. In order to increase miRNA levels, in the
common laboratory practice premiRNAs are usually preferred to
mature miRNA, for functional issues. In fact, premiRNA is partially
processed by the cellular miRNA processing machinery that makes
it more similar to ‘physiological’ miRNA.
For this reason, after the achievement of the proof-of-principle data
shown in Figures 1, 2, 3, and 4A–4D, we tried to transfect premiRNA
molecules with argininocalix[4]arene 1. As a representative example,
the data obtained using premiR-210 are shown.
Transfection of PremiRNA Using Argininocalix[4]arene 1
In Figures 4E–4H, both cell lines were transfected with two different
premiR-210 concentrations, commonly used with commercially
available transfection agents.44 The final concentration of argininoca-
lix[4]arene 1 was 10 mM. The increase of miR-210 intracellular con-
centration with respect to untransfected samples was determined
using qRT-PCR and let-7c and small nuclear RNA (snRNA) U6 as
reference. In both cell lines, the levels of miR-210 were significantly
increased after 24 h transfection. Moreover, when a comparative anal-
ysis was performed between argininocalix[4]arene 1 and a limited
panel of the most efficient commonly used commercially available
transfection agents, Lipofectamine LTX, Lipofectamine RNAiMAX,
and siPORT, at the same premiR-210 concentration, the argininoca-
lix[4]arene was found at least 10-fold more active than all of these
(Figures 4F and 4H).
The experiments described in Figures 5A–5D were designed to find
the optimal transfection conditions, when argininocalix[4]arene 1
was used as vehicle and premiR as the molecule to be carried. First
of all, we tried to set up the optimal premiRNA concentration, using
the same vehicle concentration (10 mM) for each point (Figures 5A
and 5C). The collected results demonstrated that using argininoca-calculated using qRT-PCR. To calculate fold change and CT values, three independent
transfection. (E and G) two different concentrations (70 and 200 nM) of premiR-210 wer
determined 24 h after premiRNA transfection, using qRT-PCR. (F and H) Three co
Lipofectamine LTX (gray boxes), and siPORT (black boxes) were compared with arginino
were expressed as miR-210 fold change in transfected samples with respect to untran
shown ±. p < 0.05 (*, significant), p < 0.01 (**, high significance).lix[4]arene 1 at 10 mM, 70 nM and 15 nM premiR-210 should be
used to obtain efficient uptake by U251 and K562 cells, respectively.
After this set of experiments, concentration of argininocalix[4]arene
1 was progressively reduced to verify whether at low values effi-
cient premiR-210 transfection was still supported. Four different
decreasing concentrations of argininocalix[4]arene 1 were investi-
gated (from 10 mM to 1.25 mM), and the miR-210 fold increase
with respect to control was determined by qRT-PCR. For both cell
lines, vector argininocalix[4]arene 1 at 1.25–2.5 mM concentrations
was sufficient to efficiently deliver premiR-210. From the qualitative
point of view, since the qRT-PCR quantifies the mature miR-210, the
experiments shown in Figure 5 demonstrate that premiR-210 pro-
cessing to mature miR-210 occurs within both the U251 and K562
transfected cells.
In all the experiments depicted in Figures 3, 4, and 5A–5D, the trans-
fection of miRNA/argininocalix[4]arene 1 formulations were per-
formed using the protocol indicated by Bagnacani et al.37 and
described in detail in the Materials and Methods section. In brief, a
mix containing culture medium, without FBS, argininocalix[4]arene
1, and the molecule that needs to be carried is prepared and after
20 min of incubation at room temperature is transferred to cells. After
5 h contact, the miRNA/argininocalix[4]arene 1 formulation is
removed and replaced with fresh culture medium.While this protocol
is well suited for biotech experiments (i.e., highly efficient transfection
to target cells in vitro), it is clearly not suited when protocols are de-
signed for pre-clinical therapeutic approaches, when the exposure to
the putative therapeutic treatment should be performed in contin-
uous, and not in “pulse” fashion. For this reason, we evaluated the
possibility to maintain the transfection mix in contact with cells for
all the treatment time, as anticipated in Figure 1. Starting from the hy-
pothesis that in the case of a continuous contact, a smaller amount of
argininocalix[4]arene 1 is required, we tested three different concen-
trations of argininocalix[4]arene 1 (1.25, 2.5, and 10 mM) and
compared miR-210 increase obtained after 5 h contact with that ob-
tained after continuous contact (24 h). As expected from the data
demonstrating no toxicity of long-term cultures, the results obtained
show that transfection dependent on argininocalix[4]arene 1 was
more efficient in continuous cultures (Figures 5E and 5F).
Transfection of AntagomiRNA Molecules with Argininocalix[4]
arene 1
Not only miRNA and premiRNA, but also antagomiRNA molecules,
which are usually used to reduce miRNA levels, require an adequate
delivery system. Normally, commercially available delivery systems
are able to vehicle both premiRNA and antagomiRNA molecules, us-
ing similar transfection conditions. Starting from this consideration,experiments were performed, and average ± SD values are shown. (E–H) PremiRNA
e transfected in both cell lines: U251 (E) and K562 (G) and miR-210 fold change was
mmercial available transfection agents, Lipofectamine RNAiMAX (white boxes),
calix[4]arene 1 using U251 (F) and K562 (H) as experimental model systems. All data
sfected samples. The average ± SD values of three independent experiments are
Molecular Therapy: Nucleic Acids Vol. 18 December 2019 753
(legend on next page)
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www.moleculartherapy.orgwe verified the ability of argininocalix[4]arene 1 to carry antago-
miRNA molecules into cells (Figures 6A and 6B). We tested two
different antagomiRNA molecules, antimiR-210 (Figure 6A, white
bars), which was transfected into K562 cells, and antimiR-221 (Figure
6B, white bars), transfected into U251 cells which express miR-221 at
high levels. Moreover, a comparison between argininocalix[4]arene 1
(white bars) and one of themost efficient commercially available trans-
fection agents was performed (black bars). Similar miRNA level de-
creases were observed for both antimiR-210 and antimiR-221 delivered
with the calixarene. Furthermore, miRNA decrease seems to be greater
when argininocalix[4]arene 1 was used as transfection agent with
respect to Lipofectamine RNAiMAX.
PremiRNA and AntimiRNA Molecule Transfection Using
Argininocalix[4]arene 1 to Erythroid Precursor Cells (ErPCs)
Since all the previously shown experiments were performed in
immortalized cell lines, to further investigate the potentiality of ar-
gininocalix[4]arene 1, we also employed a primary cell model, the
erythroid precursors isolated from peripheral blood, which also
are generally poorly transfected (Figure 6). The employment of
ErPCs54 allowed us to verify the behavior of argininocalix[4]arene
1 in a more “physiological” model. Transfection was performed ac-
cording to the “standard” protocol, 10 mMof vector and 5 hmix con-
tact, using both premiR-210 (Figure 6, panel C) and antimiR-210
(Figure 6, panel D). Intracellular miR-210 levels in ErPCs, isolated
from three different donors, were quantified using qRT-PCR, miR-
210 fold change was calculated with respect to the control sample
(no transfected sample), and snRNA U6 was employed as internal
reference. This experiment demonstrates that argininocalix[4]arene
1 is an excellent transfection reagent for primary cells (Figures 6C
and 6D).
MicroRNAs are intensely studied because of their ability to modulate
target mRNA, so the alteration of intracellular miRNA content
is actually only the first step to verify the effectiveness of the
transfection experiments. In fact, is important to verify if miRNA
modulation is able to modify the expression of its target
mRNA; that represents the real goal of miRNA-based therapy. It
was then essential for us verify if premiRNA or antimiRNAmolecules
carried by argininocalix[4]arene 1 were able to generate the final bio-
logical effect. Regarding premiR-210, we started with what was previ-
ously demonstrated by Gasparello et al.44 In brief, miR-210-3p is able
to target mRNA of BCL11A, one of the most studied gamma globinFigure 5. PremiRNA Transfection with Argininocalix[4]arene 1
(A–D) Setup of the experimental conditions. The optimal transfection protocol was
miR-210 fold change in transfected cells with respect to control (untransfected ce
concentration of premiR-210 (from 5 to 200 nM) were tested using for each point t
different concentrations of argininocalix[4]arene 1 (1.25, 2.5, 5, and 10 mM) were test
presented as the average of three independent experiments ± SD. (E and F) Pre
transfection protocols were tested. In the first protocol, a mix containing premiR-210
was removed and replaced with new fresh medium (black bars). In the second cas
cells for all the treatment time (white bars). The two protocols were tested in U251 (E
values ± SD was reported. p < 0.05 (*, significant), p < 0.01 (**, high significance).gene repressors. For this reason, we transfected ErPCs cells, the
most suited cellular model for this kind of experiment, with pre-
miR-210 using argininocalix[4]arene 1 (Figure 6E). BCL11A-XL
mRNA expression was analyzed using qRT-PCR 48 h after the
transfection, and fold change with respect to the control sample
was calculated. This experiment demonstrated that, as expected, the
formulation premiR-210/argininocalix[4]arene 1 is able to induce a
decreased BCL11A mRNA content.
Therapeutic Potential of Argininocalix[4]arene 1 as Vehicle of
antimiRNA Molecules: Delivery of AntimiR-221 to U251 Glioma
Cells
As demonstrated in several studies,42,43,55–57 miR-221-3p is involved
in the apoptotic pathway, and its downregulation causes the increase
of apoptotic mechanisms in several cell lines. Consequently, if anti-
miR-221 delivered by argininocalix[4]arene 1 is able to decrease
miR-221 levels in cells, an increase of apoptotic cells should be de-
tected. U251 cells were transfected with antimiR-221 at a final con-
centration of 70 nM, using 2.5 mM argininocalix[4]arene 1.
The mixture argininocalix[4]arene 1/antimiR-221 was maintained
in contact with cells for 72 h, and then the percentage of apoptotic
cells was determined (Figure 7). In order to evaluate the percent-
age of apoptotic cells, annexin V assay was performed, and cell
population plots are reported in Figure 7A. As it is possible to
see in Figure 7A, cell population, on the base of the fluorescence
levels, is divided into four groups: live cells, early apoptotic cells,
late apoptotic cells, and dead cells. Mean values for each sample
are reported in Figure 7B, while the percentage of apoptotic cells
in each representative sample is reported in the plots in Figure 7A.
When cells are transfected with antimiR-221 delivered by argini-
nocalix[4]arene 1, a significant increase of the percentage of
apoptotic cells is detected. Moreover, when only argininocalix[4]
arene 1 was employed, an increase of apoptotic cells
was noticed, even if lower than the value observed for antimiR-
221 delivered with argininocalix[4]arene 1. Interestingly, the
apoptotic profile observed is significantly different between sample
treated with only argininocalix[4]arene 1 and cells treated with
antimiR-221 transfected with argininocalix[4]arene 1; in fact,
while the percentage of early apoptotic cells in the two samples
are very similar, a marked difference is reported in the case of
late apoptotic cells. Percentage of late apoptotic cells in the calix-
arene sample is marked lower than the percentage reported forsetup for both U251 (black boxes) and K562 (white boxes) cells. In histograms,
lls) was calculated 24 h after the transfection. In (A) and (C), incremental final
he same argininocalix[4]arene 1 concentration (10 mM), while in (B) and (D), four
ed using for each point the same premiR-210 concentration (35 nM). All data are
miRNA transfection with argininocalix[4]arene 1: protocol setup. Two different
and argininocalix[4]arene 1 was maintained in contact with cells for 5 h and then
e, a premiR-210/argininocalix[4]arene 1 mixture was maintained in contact with
) and K562 (F) cell lines. Experiment was performed in triplicate and the average
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Figure 6. Transfection of AntagomiRNA Molecules with Argininocalix[4]arene 1
(A and B) AntimiRNAmolecules transfection with argininocalix[4]arene 1. Two different antagomiRNAmolecules were transfected using argininocalix[4]arene 1 (white boxes):
antimiR-221 was transfected in U251 cells (A), while antimiR-210 was transfected in the K562 cell line (B). Moreover, the argininocalix[4]arene 1 transfection efficiency was
compared with Lipofectamine RNAiMAX (black boxes), used according to the manufacturer’s instructions. Fold changes of miR-221 and miR-210 in transfected samples
with respect to control samples (untransfected cells and cells treated with vectors alone) were calculated, and the average values ± SD was reported. (C and D) PremiRNA
and antimiRNA molecules transfection with argininocalix[4]arene 1 in erythroid precursor cells (ErPCs). ErPCs isolated from three different donors were transfected with both
premiR-210 (C) and antimiR-210 (D), using argininocalix[4]arene 1 as vehicle. Content of miR-210 in samples was determined using qRT-PCR, and the expression change of
miR-210 was calculated using 2DDCT method considering untransfected cells as reference sample. The average ± SD of three independent experiments was reported. (E)
Biological effect of premiR-210 in ErPcs. Erythroid precursor cells isolated from three different donors were transfected with premiR-210 (final concentration 200 nM) and
argininocalix[4]arene 1 (final concentration 2.5 mM). 48 h after the transfection RNA was extracted and BCL11A-XL expression was analyzed using qRT-PCR. p < 0.05
(*, significant), p < 0.01 (**, high significance).
Molecular Therapy: Nucleic AcidsantimiR-221 delivered with argininocalix[4]arene 1, and also com-
parable with the average values observed in the control sample.
The extent of apoptosis induction was somehow low, considering
the strong inhibition of miR-221-3p caused by the antimiR-221
delivered with argininocalix[4]arene 1. This is not surprising,
considering the fact that other anti-apoptotic miRNAs have
been reported to play a role in glioma cell line, such as miR-
222-3p and miR-155-5p. In this case, a combined therapy based
on the co-delivery of antagomiRNAs targeting different anti-
apoptotic miRNAs can be considered to maximize apoptosis in-
duction, as reported by Brognara et al.43 and, more recently, by
Milani et al.57756 Molecular Therapy: Nucleic Acids Vol. 18 December 2019Therapeutic Potential of Argininocalix[4]arene 1 as Vehicle of
PremiRNAs: Delivery of miR-124-3p to U251 Glioma Cells
The miRNA miR-124-3p is a well-established oncosuppressor
miRNA.45,46 Accordingly, forced miR-124 expression in glioma
cell lines and in other in vitro tumor cellular systems leads to deep
changes, including inhibition of cell growth, increased chemo-
and radio-sensitivity, and induction of apoptosis. Mimicking
miR-124 has been proposed as a miRNA replacement therapy to
exert anti-tumor effects both in vivo and in vitro. We have elsewhere
reported induction of apoptosis by transfection of premiR-
124.17,45,46 For these reasons, we delivered premiR-124 with the














































Figure 7. Biological Effects of AntimiR-221 Delivered to U251 Cells by Argininocalix[4]arene 1
Glioma U251 cells were untreated () or cultured in the presence of compound argininocalix[4]arene 1 (ctrl 1), antimiR-221, or argininocalix[4]arene 1 + antimiR-221, as
indicated. (A) Representative apoptosis profile plots. (B) Quantitative data representing the average ± SD of three independent quantifications (values of untreated cells
subtracted) p < 0.01 (**, high significance).
www.moleculartherapy.orgargininocalix[4]arene 1 was able to transfect to the glioma U251
cells large amounts of premiR-124 (Figure 8A). Notably, addition
of argininocalix[4]arene 1 does not increase miR-124 levels, demon-
strating no induction effects of argininocalix[4]arene 1 on endoge-
nous miR-124 production. Furthermore, addition of miR-124 in the
absence of argininocalix[4]arene 1 was unable to enter the cells. By
contrast, large amounts of miR-124 were internalized by the treated
U251 cells (Figure 8A), leading to significant increase of apoptosis
(Figures 8B and 8C).
Therapeutic Potential of Argininocalix[4]arene 1 as Vehicle of
PremiRNAs: Delivery and Biological Effects of miR-93-5p to
IB3-1 Cystic Fibrosis Cells
In order to further demonstrate that the biological activity of deliv-
ered premiRNA molecules is maintained when argininocalix[4]arene
1 is employed, we have used the well-characterized premiR-93, which
has been elsewhere reported to exert anti-inflammatory properties,
since it inhibits the expression of IL-8 and IL-6.47,48
The experiment performed is shown in Figure 9, which demonstrates
the increase of cellular miR-93-5p content only in cystic fibrosis IB3-1
cells treated with premiR-93 delivered with compound argininocalix
[4]arene 1 (Figure 9A). This was associated with significant inhibition
of IL-8 and IL-6 mRNAs (Figure 9B) and, more importantly, for a
therapeutic point of view, decrease of the release of IL-8 and IL-6 (Fig-
ure 9C). This demonstrates that the argininocalix[4]arene 1 is able to
deliver premiRNA molecules that maintain the expected biologicalfunctions (in this case a sharp inhibition of release of the pro-inflam-
matory IL-8 and IL-6 proteins).47,48
DISCUSSION
miRNAs (or miRs) are short non-coding RNA molecules, which
act as gene regulators by repressing translation or by inducing
the cleavage of target RNA transcripts.1,3,4 Emerging evidence sug-
gests that the altered expression of miRNA may be involved in the
pathogenesis of several severe human diseases.8–15 This opens new
avenues in the field of therapeutic strategies, i.e., miRNA targeting
or miRNA mimicking.18,19 In the case of antimiRNA strategy, the
cells can be transfected with a variety of antimiRNA molecules and
the target miRNA inhibited.21 In these conditions, upregulation of
mRNA due to the targeted miRNA is obtained. For instance, Dha-
nasekaran et al.58 demonstrated that antimiR-17 therapy delays
tumorigenesis in MYC-driven hepatocellular carcinoma (HCC).
Broderick and Zamore59 found that antimiRNA-23a oligonucleo-
tide suppresses glioma cells growth by targeting apoptotic protease
activating factor-1. Feng et al.60 were able to target the seed region
of miR-155 with antimiR molecules, demonstrating that this
approach was associated with inhibition of malignant progression
of multiple myeloma cells.
In the case of miRNA mimicking strategy, cells can be transfected
with premiRNA molecules, causing a downregulation of miRNA-
regulated mRNAs. For instance, Zhu et al.61 found that elevated
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www.moleculartherapy.orgYB-1 and P-gp, mimicking the effect of YB-1 knockdown in the sensi-
tivity of MCF-7/ADM cells to anticancer agents, whereas restoration
of YB-1 diminished this effect. More recently, Xu et al.62 demon-
strated that miR-19b attenuates H2O2-induced apoptosis in rat
H9C2 cardiomyocytes via targeting the PTEN network. These data
indicate that miR-19b overexpression might be a novel therapy for
myocardial I-R injury. Finally, Koo and Kwon63 found that miR-
4779 suppresses tumor growth by inducing apoptosis and cell cycle
arrest through direct targeting of PAK2 and CCND3.
In this context, the efficient and non-toxic delivery of premiRNA and
antimiRNA molecules might be of great interest.8–15 This work
should be considered an extension of the study published by Bagna-
cani et al.,37 who recently reported the very interesting example of the
delivery of plasmid DNA using a macrocyclic cone calix[4]arene as
scaffold for non-viral vectors, displaying two spatially well-defined re-
gions, one apolar at the lower rim and one polar at the upper rim.
The aim of the present paper was to determine whether the arginino-
calix[4]arene 1 is able to efficiently deliver miRNA, premiRNA, and
antimiRNA molecules to target cells preserving their biological
activity. The following conclusions can be drawn from the obtained
results: (1) since the toxicity of argininocalix[4]arene 1 is low (see Fig-
ure 2), it can be proposed for long-term treatment of target cells, this
feature being a pre-requisite for the development of therapeutic pro-
tocols; (2) the delivery of premiRNA and antimiRNA molecules is
efficient, being higher when compared with the reference gold-stan-
dard available; (3) the biological activity of the premiRNAs and
antimiRNA is maintained (see Figures 6, 7, 8, and 9), suggesting
possible applications in the field of miRNA therapeutics.
This was demonstrated using the argininocalix[4]arene 1 in miRNA
therapeutic approaches performed on three well-described experi-
mental model systems, (1) the induction of apoptosis by antimiR-
221 in U251 cells,42,43 (2) the induction of apoptosis by premiR-124
in U251 cells,45,46 and (3) the inhibition of pro-inflammatory IL-8
and IL-6 genes in cystic fibrosis IB3-1 cells.47,64,65 Our results demon-
strate that the argininocalix[4]arene 1 should be considered a very
useful delivery system for efficiently transferring to target cells both
premiRNAs and antimiRNA molecules, preserving their biological
activity. The argininocalix[4]arene 1 was found to be not toxic under
the employed experimental conditions.
Conclusions
The major conclusion of this study is that the argininocalix[4]arene 1
is able to efficiently deliver miRNA, premiRNA, and antimiRNAmol-
ecules to target cells preserving their biological activity. In addition,
our study shows that this delivery activity is accompanied by absence
of cytotoxicity effects and anti-proliferative activity. Therefore, argi-Figure 8. Biological Effects of PremiR-124 Delivered to U251 Cells by Arginino
Glioma U251 cells were cultured for 3 days without additions () or in the presence o
124, as indicated. (A) Content of miR-124-3p following the described treatments. (
average ± SD (n = 3).ninocalix[4]arene 1 and analogs can be proposed for long-term treat-
ment of target cells, this feature being a pre-requisite for the develop-
ment of therapeutic protocols. In comparison with well-established
transfection reagents for RNA delivery, argininocalix[4]arene 1 was
found to be more efficient. When considered together, our results
demonstrate that the argininocalix[4]arene 1 should be considered
a very useful delivery system for efficiently transferring to target cells
both premiRNAs and antimiRNA molecules, maintaining their bio-
logical activity. While this manuscript is focused on in vitro delivery
of RNA-based biodrugs, the experimental systems described in this
manuscript might be in the future proposed for in vivo validation,
which will clarify the possible employment of argininocalix[4]arene
1 and analogs in therapeutic protocols.
MATERIALS AND METHODS
Synthesis and Characterization of Argininocalix[4]arene 1
The synthesis and characterization of argininocalix[4]arene 1 were
previously reported.37 Argininocalix[4]arene 1 employed for miRNA
delivery experiments was re-suspended in a solution of water:etha-
nol:DMSO (2:2:1) in sterile conditions.
Cell Lines and Culture Conditions
The human glioma U251,39 the cystic fibrosis IB3-1,40 and chronic
myelogenous K56241 cells were cultured in a humidified atmosphere
of 5% CO2/air. U251 and K562 cells were maintained in RPMI-1640
medium (Gibco, Life Technologies, Monza, Italy) supplemented
with 10% (v/v) fetal bovine serum (FBS; Biowest, Nuaillé, France),
100 units/mL penicillin, and 100 mg/mL streptomycin (pen-strep;
Sigma-Aldrich, St. Louis, MO, USA); while IB3-1 cell line was
cultured in LHC-8 medium (Thermo Fisher Scientific, Waltham,
MA, USA) supplemented with 5% of FBS. Erythroid precursor cells
(ErPCs) were isolated from peripheral blood using a two-phase
liquid medium selection procedure.54 The use of human material
was approved by the Ethics Committee of Ferrara’s District, docu-
ment number 06/2013, approved on 20 June 2013. All samples of pe-
ripheral blood have been obtained after receiving written informed
consent.
Transfection Procedures
Two different protocols were employed to transfect miRNA-based
molecules with argininocalix[4]arene 1: (1) short-term transfection
protocol (similar to that proposed by Bagnacani et al.37 for plasmidic
DNA); (2) continuous contact protocol. In brief, a mixture contain-
ing RPMI-1640 medium, argininocalix[4]arene 1 at appropriate con-
centration, and miRNA-based molecules (premiRNA, antimiRNA,
or mature miRNA) was prepared and incubated for 20 min at
room temperature, without serum. After the incubation, 10% (v/v)
of FBS was added. Cell culture medium was removed and replaced
with the transfection mixture. Transfection mixture was maintainedcalix[4]arene 1
f argininocalix[4]arene 1 (ctrl 1), premiR-124, or argininocalix[4]arene 1 + premiR-
B) Representative apoptosis profile plots. (C) Quantitative data representing the




























































































































































Figure 9. Biological Effects of PremiR-93Delivered to
Cystic Fibrosis IB3-1 Cells by Argininocalix[4]arene 1
IB3-1 cells were cultured for 3 days without additions () or
in the presence of argininocalix[4]arene 1 (ctrl 1),
premiR-93, or a premiR negative control, both delivered by
compound 1. Intracellular content of miR-93 is shown in
(A). In (B) and (C) are reported the effects of the treatments
on IL-8 and IL-6 mRNA (assayed by qRT-PCR and shown
in [B]) and on IL-8 and IL-6 released by the treated IB3-1
cells (assayed by Bioplex analysis and shown in [C]). The
data represents the average ± SD (n = 3). p < 0.05 (*, sig-
nificant), p < 0.01 (**, high significance), and p < 0.001
(***, very high significance).
Molecular Therapy: Nucleic Acidsin contact with cells for 5 h and then replaced with fresh culture me-
dium in case of transfection protocol (1) while the mixture was main-
tained until the end of the treatment, when transfection protocol (2)
was performed. PremiRNA (premiR-210, PM10516; premiR-124,
PM10691; premiR-93, 10951; premiR negative control #1,
AM17110) and antimiRNA (antimiR-210, AM10516; antimiR-221,
AM10337) molecules were purchased from Ambion (Thermo Fisher760 Molecular Therapy: Nucleic Acids Vol. 18 December 2019Scientific, Waltham, MA, USA), while mature
miRNAs were synthesized by IDT (Integrated
DNA Technology, Coralville, IA, USA) accord-
ing to miRBase sequence. All transfections with
commercially available reagents were performed
according to manufacturer’s instructions.
Effects on Cell Morphology and Cell Growth
The effects on cell morphology and cell growth
were determined 48 and 72 h after transfection,
testing different concentrations of calixarene-
based molecule. The effects on cell growth were
studied by determining the cell number/mL us-
ing a Z2 Coulter counter (Coulter Electronics,
Hialeah, FL, USA).
FACS Analysis
Uptake of a fluorescent, mature miRNA (miR-
210, IDT) was evaluated using FACScan (BD,
Franklin Lakes, NJ, USA). Cells were detached,
washed twice with Dulbecco’s phosphate-buff-
ered saline (DPBS) 1, resuspended in 150 mL
of DPBS 1, and analyzed by FACS analysis
for fluorescein isothiocyanate (FITC) fluores-
cence. For each sample, 30,000 events were ac-
quired, and data analysis was performed using
CellQuest Pro software (BD, Franklin Lakes,
NJ, USA).
RNA Extraction
Cultured cells were collected by centrifugation at
1,200 rpm for 10 min at 4C, washed with cold
DPBS 1, and lysed with Tri-reagent (Sigma Al-drich, St. Louis, MO, USA), according to manufacturer’s instructions.
Isolated RNA was washed once with cold 75% ethanol, air-dried, and
dissolved in nuclease-free water before use.
Quantification of miRNAs
For miRNA quantification, obtained RNA was reverse transcribed
using a TaqMan microRNA reverse transcription kit (Applied
Table 1. Employed TaqMan Assays







Interleukin-8 mRNA IDT Hs.PT.58.38869678.g




18S ribosomal RNA Applied Biosystems 4310893E
aAssay employed for amplification of BCL11A transcripts in K562 cells.
bAssay used for amplification of BCL11A transcripts in erythroid precursor cells.
www.moleculartherapy.orgBiosystems, Foster City, CA, USA) and specific stem-loop primers
(hsa-miR-210-3p, ID: 000512; hsa-miR-221-3p, ID: 000524; hsa-
miR-124-3p, ID: 001182; hsa-miR-93-5p, ID: 001090). qRT-PCR
was performed according to the manufacturer’s protocols and as
indicated elsewhere.42,44 All RT reactions, including RT-minus
controls and no-template controls, were run in duplicate using
the CFX96 touch real-time PCR detection system (Bio-Rad, Her-
cules, CA, USA). The relative expression was calculated using
the comparative cycle threshold (DDCT) method and U6 snRNA
(hsa U6 snRNA, ID: 001973) and hsa-let-7c (hsa-let-7c, ID:
000379) as endogenous controls.
Quantification of mRNA by qRT-PCR
BCL11A mRNA expression was analyzed using qRT-PCR. 500 ng of
RNA were reverse transcribed using TaqMan reverse transcription
reagents (Applied Biosystems) and random hexamers. qRT-PCR ex-
periments were carried out using a 50 nuclease assay with primers and
probes. The cDNA (1 mL) was amplified for 40 PCR cycles using
TaqMan universal PCR master mix 2 (Applied Biosystems). Rela-
tive expression was calculated using the DDCT method and the
endogenous controls human 18S rRNA and human RPL13A were
used as normalizer genes. Employed TaqMan assays are reported in
Table 1.
Analysis of Apoptosis
Analysis of apoptotic profile on U251 cells, transfected with
antimiR-221 or premiR-124, was performed using Muse annexin V
and dead cell kit (Millipore, Billerica, MA, USA) as indicated else-
where.42,43 In brief, 100 mL of suspension cells was added to 100 mL
of Muse annexin V and dead cell reagent, incubated at room temper-
ature, protected from the light for 20 min and analyzed using Muse
cell analyzer (Millipore, Billerica, MA, USA).
Bio-Plex Analysis
Cytokines released in culture medium by IB3-1 cells were measured
by Bio-Plex cytokine assay (Bio-Rad, Hercules, CA, USA) as
described elsewhere.64,65 The Bio-Plex cytokine assay is designed
for the multiplexed quantitative measurement of multiple cytokinesin a single well using as little as 50 mL of sample. The pre-mixed multi-
plex beads of the Bio-Plex human cytokine human 27-plex panel
(Bio-Rad, cat. # 171-A11127) were used, which included 27 cytokines
(IL-1b, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-10,
IL-12 [P70], IL-13, IL-15, IL-17, fibroblast growth factor-
basic [FGF-basic], eotaxin, granulocyte-colony stimulating factor
[G-CSF], granulocyte-macrophage colony-stimulating factor [GM-
CSF], interferon-g [IFN-g], interferon gamma-induced protein 10
[IP-10], monocyte chemoattractant protein-1 [MCP-1] [chemotactic
and activating factor, MCAF], macrophage inflammatory protein-1
alpha and beta [MIP-1a, MIP-1b], platelet-derived growth factor-
BB [PDGF-BB], RANTES, tumor necrosis factor alpha [TNF-a],
vascular endothelial growth factor [VEGF]). In brief, 50 mL of cyto-
kine standards or samples (supernatants from treated cells) were
incubated with 50 mL of anti-cytokine conjugated beads in 96-well
plates for 30 min at room temperature with shaking. Plates were
then washed three times with 100 mL of Bio-Plex wash buffer using
the Bio-Plex pro wash station (Bio-Rad, Hercules, CA, USA), 25 mL
of diluted detection antibody was added, and plates were incubated
for 30 min at room temperature with shaking. After three washes,
50 mL of streptavidin-phycoerythrin was added, and plates were incu-
bated for 10 min at room temperature with shaking. Finally, plates
were washed three times, beads were suspended in Bio-Plex assay
buffer, and samples were analyzed on Bio-Rad 96 plate reader using
the Bio-Plex suspension array system and Bio-Plex manager software
(Bio-Rad, Hercules, CA).
Statistical Analysis
Results are expressed as mean ± SEM. Comparisons between groups
were made by using paired Student’s t test. Statistical significance was
defined with p < 0.05 (*, significant), p < 0.01 (**, high significance),
and p < 0.001 (***, very high significance).
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